ENAH

Across TCGA pan-cancer cohorts, ENAH mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ENAH data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ENAH mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ENAH expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where ENAH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	54	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	18	view →
LSCC	DFS	Tertile	II,III,IV	0.539	0.842	.010	7	view →
HNSC	DFS	Median	II,III,IV	0.967	0.904	.034	5	view →
LUAD	OS	Quartile	II,III,IV	0.812	0.419	.007	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ENAH–CCRCC (DFS)

Open the CCRCC breakdown →